COLORECTAL CANCER METASTATIC

This study is testing if adding valproic acid, a drug used for epilepsy, to standard cancer drugs can better control advanced colorectal cancer that has returned after prior treatment. It will involve about 130 patients whose cancer has spread and who have already been treated wi…

This early-stage study is testing a new approach for people with colorectal cancer that has spread to the liver. Researchers want to see if a drug called Nelitolimod, delivered directly to the liver through a special catheter, is safe and feasible to use before surgery. The goal …

This early-stage study is testing a new type of personalized cell therapy called CNA3103 for adults with metastatic colorectal cancer that has spread. Doctors will collect a patient's own immune cells, modify them in a lab to target a specific protein (LGR5) on cancer cells, and …

This study is testing a two-part treatment for cancers that have spread to the liver. First, doctors use a procedure that heats and destroys tumors. Then, patients receive an immunotherapy drug. The goal is to see if this combination is more effective and safe than current option…

This study is testing whether a drug called regorafenib can help control advanced colorectal cancer that has spread and returned after initial treatment. Researchers want to see if this less intensive approach can slow cancer growth while maintaining patients' quality of life bet…

This study is testing the safety and practicality of a special pump that delivers chemotherapy directly to the liver for people with colorectal cancer or bile duct cancer that has spread to the liver. Researchers want to see if the pump can be safely used and if patients can get …

This study is testing a new type of cell therapy for adults with advanced or metastatic colorectal cancer that has stopped responding to standard treatments. Doctors will give patients immune cells (CAR-NK cells) that are engineered to recognize and attack two specific proteins f…

This study is testing the safety and effectiveness of combining two drugs, VS-6766 and cetuximab, for people with advanced colorectal cancer that has a specific genetic change called a KRAS mutation. The study is for people whose cancer has continued to grow despite trying standa…

This study is for people with advanced colorectal cancer that has spread and has a specific genetic change called BRAF V600E, and whose cancer has worsened after at least one prior treatment. It aims to see if a new combination of two targeted drugs (tunlametinib and vemurafenib)…

This study is testing a new oral drug, ABT-301, combined with two existing cancer immunotherapies (tislelizumab and bevacizumab) for people with a specific type of advanced colorectal cancer that has spread. The main goals are to find the safest dose of the new drug and see if th…

This study is testing whether a new version of an existing chemotherapy drug, packaged in tiny fat bubbles called liposomes, works better and is safer when combined with other cancer drugs for advanced colorectal cancer. It's for patients whose first treatment has stopped working…

This study aims to compare different approved liver transplant methods for patients whose colorectal cancer has spread to the liver and cannot be removed by standard surgery. Researchers will track 80 adult patients to see which transplant approach—using living or deceased donors…

This early study is testing a new, personalized vaccine designed by a special AI system. It is given along with standard chemotherapy and an immunotherapy drug to patients who have had surgery for stage III colon cancer. The main goal is to see if this three-part combination is s…

This is a small, early safety study to see if a tiny implantable device can be safely placed into liver tumors that have spread from colorectal cancer. The device, placed a few days before the patient's scheduled tumor removal surgery, releases small amounts of cancer drugs direc…

This study aims to find biological markers that can predict which patients with a specific type of metastatic colorectal cancer will not respond to the immunotherapy drug pembrolizumab. It will follow 600 patients in France who are receiving this treatment to learn why it fails f…